As a result, the IS-Micelles/aPD-L1 combination yielded TRPV1 blockade-synergized thermo-immunotherapy to efficiently suppress the tumor progression of highly intractable subcutaneous and orthotopic PDAC tumor models through reinvigorated immune responses and relieved immunosuppression. Here, TRPV1 is linked to neoplasm.